Doctors uneasy over drug for short children
A year after the US pharmaceutical regulator liberalised restrictions on a growth hormone for short but healthy children, prescriptions have increased 38%. But the popular drug, Humatrope, which is made by Eli Lilly, is controversial amongst endocrinologists. Some describe it as a necessary treatment for short children whose self-esteem might be at risk. Others call it cosmetic endocrinology.
The drug is prescribed for extremely short children in mid-puberty who are predicted to be shorter than 4 feet 11 inches as women or 5 feet 3 inches as men. It is not a remedy for the financially- challenged, as it costs between US$20,000 and $40,000 a year. Treatment is an ordeal for children, with injections needed nearly every day. Height gain is also unpredictable, with some kids spurting up 5 inches; others 1 or 2; and others none at all.
Some doctors also question whether short children are really disadvantaged in life. A recent study in the journal Pediatrics reported that shortness was not a good predictor of how well they were liked or how many friends they had.
- Prescribe morning-after pills to young teenagers, say US pediatric group - November 30, 2012
- Bahrain sentences protest docs to prison - November 28, 2012
- Terry Pratchett assisted suicide documentary wins International Emmy - November 27, 2012
More Stories
Mortality rates for American kids are rising for the first time in 50 years
US President Joe Biden is so concerned about the future of American children that he inserted a mandate for affordable...
Will Pope Francis be composted?
Will Pope Francis be composted instead of buried in St Peter’s Basilica in Rome with his predecessors? It’s unlikely. But...
The virtues and the vices of the outrageous
A Norwegian bioethicist, Anna Smajdor, recently set out a case for “Whole Body Gestational Donation” – using the wombs of...
More than 200 people have been treated with experimental CRISPR therapies
Scientists believe that CRISPR gene editing technologies will transform medicine. But how many people have been treated so far? According...
Asia-Pacific IVF market could reach US$46 billion by 2031
According to a market survey by Allied Market Research, IVF is booming in the Asia-Pacific region. The market size was...
Third global summit on human genome editing: Moving on after the He experiment
The much anticipated Third International Summit on Human Genome Editing was held in London earlier this month to explore the...